International scientists have recently developed possible correlation between Covid-19 and a trial drug APN01 in treating early stage covid patients. The drug may be effective in reducing the covid-19 load that enters lungs and other vital organs. The collaborative study offers key insights on how covid-19 infects cells of the body, including in blood vessels and kidneys. The researchers tested a genetically modified variant of the spike protein in SARS-Cov2 (called hrsACE2) to see if the virus could be halted from infecting the cells. The results are promising indicating that hrsACE2 reduced viral growth of SARS-Cov-2 by a factor of 1000-5000 in cell cultures.
The biotech company Apeiron Biologics which is the developer of the drug APN01 is planning to initiate clinical pilot study on infected covid patients in China. It should be noted that the virus causing covid-19 is a closely related to the first SARS virus. This has helped the scientists identify ACE2 as the entry point for SARS-Cov-2 ( the virus that causes the disease that we all know today as Covid-19). For more information on this critical study please review the full technical findings here. For an overview of this project we also recommend reviewing the findings of this study here.